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In the course of multistep oncogenesis, initially normal cells acquire several new functions that render them
malignant. We have recently demonstrated that the peritoneal microenvironment promotes resistance to anoikis in
ovarian cancer cells by reprogramming SRC/AKT/ERK signaling and metabolism. These ﬁndings have prognostic and
therapeutic implications.
In 2000, Hanahan and Weinberg ini-
tially proposed 6 cancer hallmarks: sus-
taining proliferative signaling, evading
growth suppressors, resisting cell death,
enabling replicative immortality, inducing
angiogenesis, and activating invasion and
metastasis.1 The subsequent remarkable
progress in cancer research, with more
than 1.5 million cancer-related papers
published since the year 2000, promoted
their proposal of the next generation of
hallmarks of cancer in 2011.2 Four emerg-
ing hallmarks, including deregulating cel-
lular energetics, have been elucidated.
Together with an emphasis on intracellu-
lar signaling networks within several func-
tional circuits (proliferation, motility,
viability, cytostasis, and differentiation)
and a commentary section on the tumor
microenvironment, our understanding of
the cancer orchestra has been described at
a new level.
While most tumor cells acquire several
hallmarks of cancer during multistep
development, not all hallmarks and cellu-
lar signaling/functional circuits are likely
to be involved at every step of cancer
development. In fact, one or a few of these
hallmarks or circuits are likely to be differ-
entially regulated and switched on and
off at different steps of cancer
development to suit the stage-specific
pathologic requirements.
To determine the critical processes of
ovarian cancer (OC) development, we
have developed a highly aggressive OC
cell line (ID8-P1) from a less aggressive
mouse OC cell line (ID8-P0) through in
vivo passage in C57BL6 mice.3 In vivo
tumor characterization and in vitro mech-
anistic assays reveal that enhanced anoikis
resistance (but not increased proliferation,
migration, or invasion) is a critical process
responsible for this aggressiveness.3
Our data have important implications
on several levels. First, the changes associ-
ated with enhanced aggressiveness are
induced by the tumor microenvironment,
since in vitro cell culture did not induce
these alterations. In addition to various
host/stromal/immune cells, acellular com-
ponents in the microenvironment also
play critical roles in regulating cancer
cells. These include, but are not limited
to, insoluble extracellular components,
such as extracellular matrix proteins, and
soluble components, such as acellular
vesicles (i.e., exosomes), secreted proteins,
peptides, bioactive lipids, and other fac-
tors. In addition, gaseous components,
including O2 and NO, play important
roles in regulating the properties of
cancer cells. Both genetic and epigenetic
changes in ID8 cells may occur, which
appear to be stable; after at least 20 in
vitro passages, the aggressive tumorigenic
potential of ID8-P1 cells is stable.
Our results also emphasize the potential
differences in cellular properties in
2-dimensional cell culture systems versus
the in vivo environment.
Second, our data indicate that stresses,
including hypoxic conditions and growth
as a cell suspension in the peritoneal cav-
ity, have specifically reprogrammed the
cellular signaling circuits by enhancing
the viability circuit and by maintaining
or even suppressing other circuits, such as
proliferation and motility. This is evi-
denced by the increase in anoikis resis-
tance, but not in the proliferative,
migratory, and invasive capacities in vitro
and in vivo; by the tight correlation
between the number of surviving perito-
neal floating cells and the overall aggres-
siveness of tumor development; and by
signaling pathway analyses.3 Our data
suggest that when cells encounter great
stresses in the microenvironment, they
switch off other cellular activities to
ensure their survival. Even though cell
migration and invasion into surrounding
tissues and the subsequent colonial
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growth at these sites are the primary
causes of morbidity and mortality of
most cancer patients,4 the number of cells
surviving against initial stresses in the
peritoneal cavity is the key determinant
of how quickly and to what extent the
tumor will develop.3
Third, we have identified that the
SRC/ERK/AKT/ signaling pathway plays
a pivotal role in anoikis resistance. This
property is not only necessary, but also
sufficient to promote cell survival in sus-
pension in the peritoneal cavity,3 which is
particularly meaningful for OC, where a
large amount of living tumor cells are
present in patients’ ascites. For many
other solid tumors, metastasis is mainly
mediated via the blood stream. Similar
viability circuit switches may exist in such
cases, although the signaling molecules
may vary because the stresses in the blood
stream are likely to be different from those
in the peritoneal cavity.
Another important feature of the
aggressive ID8-P1 cells is the increase in
metabolism, and in glycolysis in particu-
lar.3 Although Otto Warburg first pro-
posed the concept of an aerobic glycolysis
switch in cancer cells as early as the 1920s,
the importance of this concept in terms of
understanding cancer origin and signaling
mechanisms, in addition to designing bet-
ter targeting strategies, has only emerged
in recent decades.2 The genomic
instability observed in tumor cells and all
other recognized hallmarks of cancer have
been considered downstream epiphenom-
ena of the initial disturbance of cellular
energy metabolism.5 We have also
revealed the connection between the SRC
pathway and glycolysis, both of which are
involved in the viability circuit.2,3 SRC
may also affect glycolysis by targeting
other mitochondrial components.6
Although the only “metabolic” drug in
clinical use is still the enzyme L-asparagi-
nase, the increasing amount of experimen-
tal evidence, combined with the number
of trials in progress, suggests that meta-
bolic drugs will soon complement stan-
dard anticancer chemotherapy and
modern biological drugs.7,8 Figure 1 is a
schematic and perspective view of our
findings.
Finally, our studies have several clinical
implications: 1) co-targeting the host envi-
ronment is important in OC; 2) the peri-
toneal floating OC cells may have value as
markers for diagnosis, prognosis, and/or
personalized treatment; 3) removing asci-
tes along with the floating cells could be
beneficial for patients with OC; and 4)
targeting a specific vulnerable stage of
tumor development and a critical circuit
may be an effective approach to therapy
development.
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derived from either ovarian surface epithelial cells or fallopian tube epithelial cells, primarily acquire
a proliferation circuit to develop into primary tumors. Reduced cell-to-cell contact and possible
induction of the epithelial–mesenchymal transition (EMT), together with enhanced cell motility, are
probably involved in the dissemination of OC cells from the primary site to the peritoneal cavity,
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supplies, as well as the need to grow as a cell suspension. These conditions reprogram the cells
into a survival circuit, in which the SRC-AKT pathway and increased glycolysis play crucial roles. The
number of surviving peritoneal ﬂoating cells directly correlates with how quickly and to what extent
metastases will develop, and thus these cells may represent the best cancer development markers
and therapeutic targets. Once tumor cells attach to the secondary sites, another circuit switch may
occur in order for them to generate sizable metastases.
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